Largest pharmaceutical companies in the United States by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
AbbVie leads the 44 pharmaceutical companies in the United States ranked by total liabilities, at TRY 6.93T, ahead of Pfizer (TRY 6.14T) and Johnson & Johnson (TRY 5.95T). Figures as of 20 Nov 2026, 06:19 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 44
- First
- AbbVieTRY 6.93T
- Median
- TRY 42.1B
- Combined market value
- TRY 188.83T
- Countries
- 1
Market values as of .
United States▾
All sectors▾
Pharmaceuticals▾
| # | Company | Total liabilities ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AbbVieABBV · Health Care | TRY 6.93T | TRY 25.33T | TRY 14,331.73 | 0.86% down | 25% up | ||
| 2 | PfizerPFE · Health Care | TRY 6.14T | TRY 7.93T | TRY 1,392.03 | 1.85% down | 15% up | ||
| 3 | Johnson & JohnsonJNJ · Health Care | TRY 5.95T | TRY 32.51T | TRY 13,502.78 | 2.04% down | 34% up | ||
| 4 | Eli LillyLLY · Health Care | TRY 4.34T | TRY 60.83T | TRY 68,293.31 | 2.29% down | 33% up | ||
| 5 | Merck & CoMRK · Health Care | TRY 4.26T | TRY 16.55T | TRY 6,712.97 | 3.61% down | 45% up | ||
| 6 | Bristol-Myers SquibbBMY · Health Care | TRY 3.62T | TRY 6.03T | TRY 2,948.84 | 2.05% down | 30% up | ||
| 7 | Abbott LaboratoriesABT · Health Care | TRY 1.72T | TRY 9.09T | TRY 5,250.18 | 0.58% down | 16% down | ||
| 8 | ViatrisVTRS · Health Care | TRY 1.14T | TRY 1.15T | TRY 1,004.85 | 1.97% down | 99% up | ||
| 9 | ZoetisZTS · Health Care | TRY 613.4B | TRY 1.66T | TRY 4,083.59 | 5.59% down | 26% down | ||
| 10 | Royalty PharmaRPRX · Health Care | TRY 500.7B | TRY 1.97T | TRY 3,422.95 | 1.38% down | 79% up | ||
| 11 | Regeneron PharmaceuticalsREGN · Health Care | TRY 470.2B | TRY 4.83T | TRY 46,670.87 | 2.35% down | 28% up | ||
| 12 | Vertex PharmaceuticalsVRTX · Health Care | TRY 352.7B | TRY 6.67T | TRY 26,317.12 | 2.94% down | 27% up | ||
| 13 | Elanco Animal HealthELAN · Health Care | TRY 344.3B | TRY 664.2B | TRY 1,328.85 | 1.54% down | 26% up | ||
| 14 | Alnylam PharmaceuticalsALNY · Health Care | TRY 211.1B | TRY 1T | TRY 7,471.67 | 1.06% down | 66% down | ||
| 15 | Amneal PharmaceuticalsAMRX · Health Care | TRY 185.6B | TRY 376.7B | TRY 1,081.17 | 2.24% down | 90% up | ||
| 16 | PTC TherapeuticsPTCT · Health Care | TRY 156.9B | TRY 246.3B | TRY 2,948.08 | 3.16% down | 21% down | ||
| 17 | Ionis PharmaceuticalsIONS · Health Care | TRY 153.4B | TRY 229.1B | TRY 1,375.85 | 0.62% down | 63% down | ||
| 18 | BridgeBio PharmaBBIO · Health Care | TRY 152.3B | TRY 769.8B | TRY 3,951.66 | 0.22% up | 21% up | ||
| 19 | CytokineticsCYTK · Health Care | TRY 105.3B | TRY 362.3B | TRY 2,601.08 | 0.27% up | 19% down | ||
| 20 | InsmedINSM · Health Care | TRY 77.1B | TRY 1.6T | TRY 7,301.83 | 20.58% up | 40% down | ||
| 21 | BioMarin PharmaceuticalBMRN · Health Care | TRY 76.2B | TRY 601.3B | TRY 3,104.52 | 0.02% down | 17% up | ||
| 22 | Arrowhead PharmaceuticalsARWR · Health Care | TRY 44.6B | TRY 311.9B | TRY 2,206.32 | 1.25% up | 13% up | ||
| 23 | United TherapeuticsUTHR · Health Care | TRY 39.6B | TRY 1.2T | TRY 28,260.10 | 3.16% down | 22% up | ||
| 24 | Legend BiotechLEGN · Health Care | TRY 37B | TRY 157.8B | TRY 813.79 | 0.92% down | 41% down | ||
| 25 | Madrigal PharmaceuticalsMDGL · Health Care | TRY 33.2B | TRY 465.8B | TRY 20,053.50 | 0.34% down | 27% down | ||
| 26 | Axsome TherapeuticsAXSM · Health Care | TRY 30.4B | TRY 360.7B | TRY 6,858.04 | 1.25% up | 6% down | ||
| 27 | Ligand PharmaceuticalsLGND · Health Care | TRY 27.5B | TRY 290.1B | TRY 14,503.58 | 3.94% down | 50% up | ||
| 28 | Mirum PharmaceuticalsMIRM · Health Care | TRY 26.7B | TRY 315.2B | TRY 4,827.62 | 3.27% up | 34% up | ||
| 29 | Travere TherapeuticsTVTX · Health Care | TRY 24.8B | TRY 234.4B | TRY 2,441.36 | 3.86% down | 45% up | ||
| 30 | TG TherapeuticsTGTX · Health Care | TRY 21B | TRY 495.7B | TRY 3,279.41 | 1.88% down | 117% up | ||
| 31 | Cogent BiosciencesCOGT · Health Care | TRY 15.2B | TRY 244B | TRY 1,402.14 | 0.25% down | 20% down | ||
| 32 | Rhythm PharmaceuticalsRYTM · Health Care | TRY 10.6B | TRY 409.3B | TRY 5,903.74 | 1.88% down | 18% up | ||
| 33 | Corcept TherapeuticsCORT · Health Care | TRY 9.5B | TRY 359.5B | TRY 3,284.46 | 4.15% down | 10% down | ||
| 34 | Definium TherapeuticsDFTX · Health Care | TRY 5.4B | TRY 204B | TRY 1,490.09 | 1.24% up | 168% up | ||
| 35 | Summit TherapeuticsSMMT · Health Care | TRY 4.7B | TRY 427.3B | TRY 534.27 | 0.67% up | 36% down | ||
| 36 | ErascaERAS · Health Care | TRY 3.6B | TRY 252.3B | TRY 718.76 | 3.34% up | 395% up | ||
| 37 | Spyre TherapeuticsSYRE · Health Care | TRY 3.2B | TRY 468.7B | TRY 4,934.78 | 3.77% down | 332% up | ||
| 38 | Praxis Precision MedicinesPRAX · Health Care | TRY 3B | TRY 439.2B | TRY 15,714.66 | 1.87% up | 86% up | ||
| 39 | Protagonist TherapeuticsPTGX · Health Care | TRY 2.7B | TRY 409.2B | TRY 6,268.68 | 2.47% down | 51% up | ||
| 40 | Dianthus TherapeuticsDNTH · Health Care | TRY 1.9B | TRY 241.5B | TRY 4,287.79 | 1.01% up | 108% up | ||
| 41 | Edgewise TherapeuticsEWTX · Health Care | TRY 1.5B | TRY 227.8B | TRY 2,080.97 | 0.48% down | 86% up | ||
| 42 | Oruka TherapeuticsORKA · Health Care | TRY 843.5M | TRY 334.5B | TRY 4,931.74 | 1.91% up | 255% up | ||
| 43 | Belite BioBLTE · Health Care | TRY 509M | TRY 310B | TRY 7,633.41 | 3.33% down | 43% up | ||
| 44 | VeradermicsMANE · Health Care | TRY 462.8M | TRY 265.3B | TRY 6,287.38 | 0.38% down | 231% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 50.5457 TRY).
Questions and answers
Which pharmaceutical companies in the United States rank first by total liabilities?
AbbVie (TRY 6.93T), Pfizer (TRY 6.14T) and Johnson & Johnson (TRY 5.95T) are the top three of the 44 pharmaceutical companies in the United States ranked by total liabilities as of 20 Nov 2026, 06:19 UTC.
How many pharmaceutical companies in the United States are in this ranking?
44 are ranked by total liabilities.
What are these pharmaceutical companies in the United States worth together?
The 44 pharmaceutical companies in the United States ranked by total liabilities have a combined market value of TRY 188.83T as of 20 Nov 2026, 06:19 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceutical companies in the United States by total liabilities”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?country=united-states&by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.